Vascular endothelial growth factor: 20th-century mechanisms, 21st- century therapies

Investigative Ophthalmology and Visual Science

Volumn 38, Issue 9, 1997, Pages 1647-1652

  Aiello, Lloyd Paul ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE A2A RECEPTOR ANTAGONIST; ANGIOGENESIS INHIBITOR; ANTISENSE OLIGONUCLEOTIDE; RECEPTOR BLOCKING AGENT; VASCULOTROPIN;

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; CELL HYPOXIA; DIABETIC RETINOPATHY; DRUG RECEPTOR BINDING; HUMAN; NEOVASCULAR GLAUCOMA; NONHUMAN; OCULAR HISTOPLASMOSIS; PRIORITY JOURNAL; RETINA ISCHEMIA; RETINA MACULA AGE RELATED DEGENERATION; RETINA NEOVASCULARIZATION; RETINA VEIN OCCLUSION; RETROLENTAL FIBROPLASIA; REVIEW; SIGNAL TRANSDUCTION; VISUAL IMPAIRMENT;

ANIMALS; ENDOTHELIAL GROWTH FACTORS; HUMANS; ISCHEMIA; LYMPHOKINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GROWTH FACTOR; RECEPTORS, MITOGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RETINAL NEOVASCULARIZATION; RETINAL VESSELS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0030824259     PISSN: 01460404     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (19)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal disease. Trans Ophthalmol Soc UK. 1948;68:137-180.
2. Miller JW, Adamis AP, Aiello LP. VEGF in ocular neovascularization and proliferative diabetic retinopathy. Diabetes Metab Rev. 1997;13:37-50.
3. Murata T, Ishibashi T, Khalil A, Hata Y, Yoshikawa H, Inomata H. Vascular endothelial growth factor plays a role in hypermeability of diabetic retinal vessels. Ophthalmic Res. 1995;27:48-52.
4. Thieme H, Aiello LP, Takagi H, Ferrara N, King GL. Comparative analysis of vascular endothelial growth factor (VEGF) receptors on retinal and aortic microvascular endothelial cells. Diabetes. 1994;44:98-103.
5. Guerrin M, Moukadiri H, Chollet P, et al. Vasculotropin/vascular endothelial growth factor is an autocrine growth factor for human retinal pigment epithelial cells cultured in vitro. J Cell Physiol. 1995;164:385-394.
6. Aiello LP, Northrup JM, Keyt BA, Takagi H, Iwamoto MA. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Opthalmol. 1995; 113:1538-1544.
7. Aiello, LP, Pierce EA, Foley ED, et al. Inhibition of vascular endothelial growth factor suppresses retinal neovascularization in vivo. Proc Natl Acad Sci USA. 1995;92:10457-10461.
8. Robinson GS, Pierce EA, Rook SL, Foley E, Webb R, Smith LEH. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci USA. 1996;93:4851-4856.
9. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of VEGF prevent ocular neovascularization in a non-human primate. Arch Ophthalmol. 1996;114:66-71.
10. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-11487.
11. Lutty GA, McLeod DS, Merges C, Diggs A, Plouet J. Localization of VEGF in human retina and choroid. Arch Ophthalmol. 1996;114:971-977.
12. Amin RH, Frank RN, Kennedy A, Eliott D, Puklin JE, Abrams GW. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Invest Ophthalmol Vis Sci. 1997;38:36-47.
13. Vinores SA, Kuchle M, Mahlow J, Chin C, Green WR, Campochiaro PA. Blood-ocular barrier breakdown in eyes with ocular melanoma: A potential role for vascular endothelial growth factor/vascular permeability factor. Am J Pathol. 1995;147:1289-1297.
14. Lopez PF, Sippy BD, Lambert HM, Thach AB, Hinton DR. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci. 1996;37:855-868.
15. Takagi H, King GL, Robinson GS, Ferrara N, Aiello LP. Hypoxic-induction of vascular endothelial growth factor (VEGF) is mediated by adenosine, adenosine A2 receptors and cAMP-dependent protein kinase A in retinal microvascular pericytes and vascular endothelial cells. Invest Ophthalmol Vis Sci. 1996;37:2165-2176.
16. Pu X, Aiello LP, Jiang ZY, Park DJ, Newsome WT, King GL. Characterization of vascular endothelial growth factor's effect on the activation of phospholipase Cγ, protein kinase C pathways and endothelial cell growth. J Clin Invest. 1996;98:2018-2026.
17. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunction in diabetic rats by an oral PKC β inhibitor. Science. 1996;272:728-731.
18. D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 1994;91:4082-4085.
19. Stone J, Chang-Ling T, Pe're J, Itin A, Gnessin H, Keshet E. Roles of vascular endothelial growth factor and astrocyte degeneration in the genesis of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 1996; 37:290-299.